Sytalizumab

N/A

Report date: 2024/11/24 20:00:04

Base Information

Drug NameSytalizumab
Drug Alias NameTWP-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 9
TargetsTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursCarcinoma, Transitional CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesTherawisdom Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTherawisdom Biopharma Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Transitional CellMelanoma

Other Information

ATC CodeN/A
Related LinksN/A